Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director · 10% owner | March 25, 2019 | March 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date March 25, 2019 · Filed March 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2025-12-01 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2025-12-01 | Direct | 15,000 |
Reported balance
After 2019-03-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-25 · Grant · Acquired 15,000 · Balance 15,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-03-25 · Disposition to issuer · Disposed 35,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-06-10 | Direct | 35,000 |
Reported balance
After 2019-03-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-25 · Grant · Acquired 35,000 · Balance 35,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2027-06-23 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-25 · Disposition to issuer · Disposed 125,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-06-23 | Direct | 125,000 |
Reported balance
After 2019-03-25 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-03-25 · Grant · Acquired 125,000 · Balance 125,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-03-25 · Disposition to issuer · Disposed 75,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-10-29 | Direct | 75,000 |
Reported balance
After 2019-03-25 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2019-03-25 · Grant · Acquired 75,000 · Balance 75,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 493,398 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 493,398 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2020-11-17 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 125,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2021-03-18 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 250,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2019-12-31 | Direct | 444,444 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 444,444 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2019-12-31 | Direct | 400,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 400,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2021-09-26 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 80,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-02-10 | Direct | 21,731 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 21,731 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-03-01 | Direct | 16,667 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 16,667 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2021-06-30 | IndirectTrust | 40,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 40,000 F3: The warrant is held by a trust established by the Reporting Person for the benefit of his immediate family. The Reporting Person serves as a trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018.
F2: The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018.
F3: The warrant is held by a trust established by the Reporting Person for the benefit of his immediate family. The Reporting Person serves as a trustee of the trust.
F4: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019.
F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020.
F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 17 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 75,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 16 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 125,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 15 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-06-23 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 125,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 14 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2027-06-23 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 35,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 9 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2026-06-10 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 35,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-06-10 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 15,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 3 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-12-01 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 15,000 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001567619-19-007597 · doc1.xml · derivative · entry 2 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-12-01 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018. Read SEC document |
| November 20, 2018 Filed Nov 20, 2018 22:08 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 400,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001567619-18-006777 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2019-12-31 F6 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price and an extended expiration date. Read SEC document |
| November 20, 2018 Filed Nov 20, 2018 22:08 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 400,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001567619-18-006777 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2018-12-31 F6 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price and an extended expiration date. Read SEC document |
| November 20, 2018 Filed Nov 20, 2018 22:08 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 444,444 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001567619-18-006777 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2019-12-31 F6 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price and an extended expiration date. Read SEC document |
| November 20, 2018 Filed Nov 20, 2018 22:08 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 444,444 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001567619-18-006777 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2018-12-31 F6 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price and an extended expiration date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:37 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004784 · doc1.xml · derivative · entry 13 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 400,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 10 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2018-12-31 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 9 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2018-12-31 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 444,444 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2018-12-31 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2018-12-31 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 250,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2021-03-18 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 250,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2021-03-18 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 125,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 4 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2020-11-17 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 125,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-043375 · doc1.xml · derivative · entry 3 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2020-11-17 F5 · price: The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price. Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 125,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-17-026106 · doc1.xml · derivative · entry 12 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-06-23 F4 · derivative.exercise_date: The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 22:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 16,667 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010334 · doc1.xml · derivative · entry 11 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2022-03-01 F1 · price: In exchange for accrued director fees. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 22:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 16,667 | $3.00 | $50,001.00 |
DisclosureSEC source: 0001140361-17-010334 · doc1.xml · nonDerivative · entry 1 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,398 F1 · price: In exchange for accrued director fees. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 21,731 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-006209 · doc1.xml · derivative · entry 10 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,731 Underlying: Common Stock · 21,731 shares Expires 2022-02-10 F4 · price: The warrant was issued in consideration of a concurrent acquisition by the Reporting Person from the Issuer of 21,731 shares. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 21,731 | $3.00 | $65,193.00 |
DisclosureSEC source: 0001140361-17-006209 · doc1.xml · nonDerivative · entry 1 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,731 Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 15:40 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-089907 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2018-12-31 F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 15:40 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | SaleWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-089907 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2018-03-18 F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 15:40 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-089907 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2018-12-31 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 15:40 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | SaleWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-089907 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2017-11-18 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 19, 2016 20:33 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-090226 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2018-12-31 F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 19, 2016 20:33 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-090226 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2018-03-18 F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. F3 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017 (subsequently extended to March 18, 2018). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 19, 2016 20:33 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-090226 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2018-12-31 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| December 14, 2016 Filed Dec 19, 2016 20:33 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-090226 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2017-11-18 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. F2 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016 (subsequently extended to November 18, 2017). The warrant expiration date was extended to December 31, 2018. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 80,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · derivative · entry 11 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2021-09-26 Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2018-03-18 F3 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | SaleWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2017-03-18 F3 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2017-11-18 F2 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | SaleWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2016-11-18 F2 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 80,000 | $3.00 | $240,000.00 |
DisclosureSEC source: 0001140361-16-080941 · doc1.xml · nonDerivative · entry 1 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseWarrant · Derivative | 80,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · derivative · entry 11 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2021-09-26 Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · derivative · entry 8 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2018-03-18 F3 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 400,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · derivative · entry 7 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2017-03-18 F3 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018. Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · derivative · entry 6 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,444 Underlying: Common Stock · 444,444 shares Expires 2017-11-18 F2 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerWarrant · Derivative | 444,444 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · derivative · entry 5 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2016-11-18 F2 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017. Read SEC document |
| September 26, 2016 Filed Dec 19, 2016 20:30 UTC Amendment | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 80,000 | $3.00 | $240,000.00 |
DisclosureSEC source: 0001140361-16-090223 · doc1.xml · nonDerivative · entry 1 Desmarais John M · CIK 0001659553 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.